Drug Metabolism Reviews最新文献_第4页

Favipiravir, remdesivir, and lopinavir: metabolites, degradation products and their analytical methods. 法维拉韦、雷米替韦和洛匹那韦：代谢物、降解产物及其分析方法。

IF 5.9 2区医学

Drug Metabolism Reviews Pub Date : 2024-02-01 Epub Date: 2024-03-06 DOI: 10.1080/03602532.2024.2326415

Mir Saleh Hoseininezhad-Namin, Elaheh Rahimpour, Abolghasem Jouyban

{"title":"Favipiravir, remdesivir, and lopinavir: metabolites, degradation products and their analytical methods.","authors":"Mir Saleh Hoseininezhad-Namin, Elaheh Rahimpour, Abolghasem Jouyban","doi":"10.1080/03602532.2024.2326415","DOIUrl":"10.1080/03602532.2024.2326415","url":null,"abstract":"Severe acute respiratory syndrome 2 (SARS-CoV-2) caused the emergence of the COVID-19 pandemic all over the world. Several studies have suggested that antiviral drugs such as favipiravir (FAV), remdesivir (RDV), and lopinavir (LPV) may potentially prevent the spread of the virus in the host cells and person-to-person transmission. Simultaneously with the widespread use of these drugs, their stability and action mechanism studies have also attracted the attention of many researchers. This review focuses on the action mechanism, metabolites and degradation products of these antiviral drugs (FAV, RDV and LPV) and demonstrates various methods for their quantification and discrimination in the different biological samples. Herein, the instrumental methods for analysis of the main form of drugs or their metabolite and degradation products are classified into two types: optical and chromatography methods which the last one in combination with various detectors provides a powerful method for routine and stability analyses. Some representative studies are reported in this review and the details of them are carefully explained. It is hoped that this review will be a good guideline study and provide a better understanding of these drugs from the aspects investigated in this study.","PeriodicalId":11307,"journal":{"name":"Drug Metabolism Reviews","volume":" ","pages":"127-144"},"PeriodicalIF":5.9,"publicationDate":"2024-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140038944","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Enantioselectivity in some physiological and pathophysiological roles of hydroxyeicosatetraenoic acids 羟基二碳四烯酸在某些生理和病理生理中的对映体选择性作用

IF 5.9 2区医学

Drug Metabolism Reviews Pub Date : 2023-11-21 DOI: 10.1080/03602532.2023.2284110

Sara A. Helal, Samar H. Gerges, Ayman O. S. El-Kadi

引用次数: 0

Bioactivation and reactivity research advances - 2022 year in review‡. 生物活性和反应性研究进展——2022年综述。

IF 5.9 2区医学

Drug Metabolism Reviews Pub Date : 2023-11-01 Epub Date: 2023-08-22 DOI: 10.1080/03602532.2023.2244193

Shuai Wang, Upendra A Argikar, Lionel Cheruzel, Sungjoon Cho, Rachel D Crouch, Deepika Dhaware, Carley J S Heck, Kevin M Johnson, Amit S Kalgutkar, Lloyd King, Joyce Liu, Bin Ma, Hlaing Maw, Grover P Miller, Herana Kamal Seneviratne, Ryan H Takahashi, Cong Wei, S Cyrus Khojasteh

{"title":"Bioactivation and reactivity research advances - 2022 year in review‡.","authors":"Shuai Wang, Upendra A Argikar, Lionel Cheruzel, Sungjoon Cho, Rachel D Crouch, Deepika Dhaware, Carley J S Heck, Kevin M Johnson, Amit S Kalgutkar, Lloyd King, Joyce Liu, Bin Ma, Hlaing Maw, Grover P Miller, Herana Kamal Seneviratne, Ryan H Takahashi, Cong Wei, S Cyrus Khojasteh","doi":"10.1080/03602532.2023.2244193","DOIUrl":"10.1080/03602532.2023.2244193","url":null,"abstract":"With the 50th year mark since the launch of Drug Metabolism and Disposition journal, the field of drug metabolism and bioactivation has advanced exponentially in the past decades (Guengerich 2023).This has, in a major part, been due to the continued advances across the whole spectrum of applied technologies in hardware, software, machine learning (ML), and artificial intelligence (AI). LC-MS platforms continue to evolve to support key applications in the field, and automation is also improving the accuracy, precision, and throughput of these supporting assays. In addition, sample generation and processing is being aided by increased diversity and quality of reagents and bio-matrices so that what is being analyzed is more relevant and translatable. The application of in silico platforms (applied software, ML, and AI) is also making great strides, and in tandem with the more traditional approaches mentioned previously, is significantly advancing our understanding of bioactivation pathways and how these play a role in toxicity. All of this continues to allow the area of bioactivation to evolve in parallel with associated fields to help bring novel or improved medicines to patients with urgent or unmet needs.Shuai Wang and Cyrus Khojasteh, on behalf of the authors.","PeriodicalId":11307,"journal":{"name":"Drug Metabolism Reviews","volume":" ","pages":"267-300"},"PeriodicalIF":5.9,"publicationDate":"2023-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10052216","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Biotransformation research advances - 2022 year in review. 生物转化研究进展-2022年回顾。

IF 5.9 2区医学

Drug Metabolism Reviews Pub Date : 2023-11-01 Epub Date: 2023-10-28 DOI: 10.1080/03602532.2023.2262161

S Cyrus Khojasteh, Upendra A Argikar, Lionel Cheruzel, Sungjoon Cho, Rachel D Crouch, Deepika Dhaware, Carley J S Heck, Kevin M Johnson, Amit S Kalgutkar, Lloyd King, Joyce Liu, Bin Ma, Hlaing Maw, Grover P Miller, Herana Kamal Seneviratne, Ryan H Takahashi, Shuai Wang, Cong Wei, Klarissa D Jackson

引用次数: 0

New strategy for rational use of antihypertensive drugs in clinical practice in high-altitude hypoxic environments. 高海拔缺氧环境下临床合理使用降压药物的新策略。

IF 5.9 2区医学

Drug Metabolism Reviews Pub Date : 2023-11-01 Epub Date: 2023-08-24 DOI: 10.1080/03602532.2023.2250930

Delong Duo, Yabin Duan, Junbo Zhu, Xue Bai, Jianxin Yang, Guiqin Liu, Qian Wang, Xiangyang Li

{"title":"New strategy for rational use of antihypertensive drugs in clinical practice in high-altitude hypoxic environments.","authors":"Delong Duo, Yabin Duan, Junbo Zhu, Xue Bai, Jianxin Yang, Guiqin Liu, Qian Wang, Xiangyang Li","doi":"10.1080/03602532.2023.2250930","DOIUrl":"10.1080/03602532.2023.2250930","url":null,"abstract":"High-altitude hypoxic environments have critical implications on cardiovascular system function as well as blood pressure regulation. Such environments place patients with hypertension at risk by activating the sympathetic nervous system, which leads to an increase in blood pressure. In addition, the high-altitude hypoxic environment alters the in vivo metabolism and antihypertensive effects of antihypertensive drugs, which changes the activity and expression of drug-metabolizing enzymes and drug transporters. The present study reviewed the pharmacodynamics and pharmacokinetics of antihypertensive drugs and its effects on patients with hypertension in a high-altitude hypoxic environment. It also proposes a new strategy for the rational use of antihypertensive drugs in clinical practice in high-altitude hypoxic environments. The increase in blood pressure on exposure to a high-altitude hypoxic environment was mainly dependent on increased sympathetic nervous system activity. Blood pressure also increased proportionally to altitude, whilst ambulatory blood pressure increased more than conventional blood pressure, especially at night. High-altitude hypoxia can reduce the activities and expression of drug-metabolizing enzymes, such as CYP1A1, CYP1A2, CYP3A1, and CYP2E1, while increasing those of CYP2D1, CYP2D6, and CYP3A6. Drug transporter changes were related to tissue type, hypoxic degree, and hypoxic exposure time. Furthermore, the effects of high-altitude hypoxia on drug-metabolism enzymes and transporters altered drug pharmacokinetics, causing changes in pharmacodynamic responses. These findings suggest that high-altitude hypoxic environments affect the blood pressure, pharmacokinetics, and pharmacodynamics of antihypertensive drugs. The optimal hypertension treatment plan and safe and effective medication strategy should be formulated considering high-altitude hypoxic environments.","PeriodicalId":11307,"journal":{"name":"Drug Metabolism Reviews","volume":" ","pages":"388-404"},"PeriodicalIF":5.9,"publicationDate":"2023-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10432881","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Drug transporters in drug disposition - the year 2022 in review. 药物处置中的药物转运蛋白——2022年回顾。

IF 5.9 2区医学

Drug Metabolism Reviews Pub Date : 2023-11-01 Epub Date: 2023-09-06 DOI: 10.1080/03602532.2023.2252618

Paresh P Chothe, Pallabi Mitra, Masanori Nakakariya, Diane Ramsden, Charles J Rotter, Philip Sandoval, Kimio Tohyama

{"title":"Drug transporters in drug disposition - the year 2022 in review.","authors":"Paresh P Chothe, Pallabi Mitra, Masanori Nakakariya, Diane Ramsden, Charles J Rotter, Philip Sandoval, Kimio Tohyama","doi":"10.1080/03602532.2023.2252618","DOIUrl":"10.1080/03602532.2023.2252618","url":null,"abstract":"On behalf of all the authors, I am pleased to share our third annual review on drug transporter science with an emphasis on articles published and deemed influential in signifying drug transporters' role in drug disposition in the year 2022. As the drug transporter field is rapidly evolving several key findings were noted including promising endogenous biomarkers, rhythmic activity, IVIVE approaches in transporter-mediated clearance, new modality interaction, and transporter effect on gut microbiome. As identified previously (Chothe et Cal. 2021, 2022) the goal of this review is to highlight key findings without a comprehensive overview of each article and to this end, each coauthor independently selected 1-3 peer-reviewed articles published or available online in the year 2022 (Table 1). Each article is summarized in synopsis and commentary with unbiased viewpoints by each coauthor. We strongly encourage readers to consult original articles for specifics of the study. Finally, I would like to thank all coauthors for their continued support in writing this annual review on drug transporters and invite anyone interested in contributing to future versions of this review.","PeriodicalId":11307,"journal":{"name":"Drug Metabolism Reviews","volume":" ","pages":"343-370"},"PeriodicalIF":5.9,"publicationDate":"2023-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10521854","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Clinical pharmacokinetics of nebivolol: a systematic review. 奈比洛尔的临床药代动力学：系统综述。

IF 5.9 2区医学

Drug Metabolism Reviews Pub Date : 2023-11-01 Epub Date: 2023-10-28 DOI: 10.1080/03602532.2023.2271195

Nida Hanif, Ammara Zamir, Imran Imran, Hamid Saeed, Abdul Majeed, Anees Ur Rehman, Waseem Ashraf, Faleh Alqahtani, Muhammad Fawad Rasool

{"title":"Clinical pharmacokinetics of nebivolol: a systematic review.","authors":"Nida Hanif, Ammara Zamir, Imran Imran, Hamid Saeed, Abdul Majeed, Anees Ur Rehman, Waseem Ashraf, Faleh Alqahtani, Muhammad Fawad Rasool","doi":"10.1080/03602532.2023.2271195","DOIUrl":"10.1080/03602532.2023.2271195","url":null,"abstract":"Nebivolol is a beta-1 receptor blocker used to treat hypertension, heart failure, erectile dysfunction, vascular disease, and diabetes mellitus. This review investigated the data regarding pharmacokinetic (PK) parameters, drug-drug interactions, dextrorotatory (D), and levorotatory (L) stereoisomers of nebivolol. The articles related to the PK of nebivolol were retrieved by searching the five databases; Google Scholar, PubMed, Cochrane Library, ScienceDirect, and EBSCO. A total of 20 studies comprising plasma concentration-time profile data following the nebivolol's oral and intravenous (IV) administration were included. The area under the concentration-time curve from zero to infinity (AUC0-∞) was 15 times greater in poor metabolizers (PMs) than in extensive metabolizers (EMs). In hypertensive patients, L-nebivolol expressed a higher maximum plasma concentration (Cmax) than D-nebivolol, i.e. 2.5 ng/ml vs 1.2 ng/ml. The AUC0-∞ of nebivolol was 3-fold greater in chronic kidney disease (CKD). The clearance (CL) was increased in obese than in controls from 51.6 ± 11.6 L/h to 71.6 ± 17.4 L/h when 0.5 mg/ml IV solution was infused. Nebivolol showed higher Cmax, AUC0-∞ and half-life (t1/2) when co-administered with bupropion, duloxetine, fluvoxamine, paroxetine, lansoprazole, and fluoxetine. This concise review of nebivolol would be advantageous in assessing all PK parameters, which may be crucial for clinicians to avoid drug-drug interactions, prevent adverse drug events and optimize the dosage regimen in diseased patients diagnosed with hypertension and cardiovascular disorders.","PeriodicalId":11307,"journal":{"name":"Drug Metabolism Reviews","volume":" ","pages":"428-440"},"PeriodicalIF":5.9,"publicationDate":"2023-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41233275","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Pregnane X receptor as a therapeutic target for cholestatic liver injury. 妊娠X受体作为胆汁淤积性肝损伤的治疗靶点。

IF 5.9 2区医学

Drug Metabolism Reviews Pub Date : 2023-11-01 Epub Date: 2023-09-10 DOI: 10.1080/03602532.2023.2248680

Huan Lan, Ying Zhang, Minqi Fan, Bingxin Wu, Caiyan Wang

引用次数: 0

Differential modulation of cytochrome P450 enzymes by arsenicals in non-human experimental models. 非人类实验模型中砷对细胞色素P450酶的差异调节。

IF 5.9 2区医学

Drug Metabolism Reviews Pub Date : 2023-11-01 Epub Date: 2023-09-07 DOI: 10.1080/03602532.2023.2254525

Mahmoud A El-Ghiaty, Sara R El-Mahrouk, Mohammed A Alqahtani, Ayman O S El-Kadi

引用次数: 0

Interaction of drugs with gut microbiota modulators. 药物与肠道菌群调节剂的相互作用。